Cardiorentis

Cardiorentis, Roche collaborate on Ularitide

Friday, October 17, 2014

Cardiorentis, a Switzerland-based, privately held biopharmaceutical company, is collaborating with Roche to establish the therapeutic efficacy and safety of Ularitide, the company’s investigational drug for acute heart failure (AHF). Cardiorentis will incorporate Roche’s advanced in vitro diagnostic tests into its TRUE-AHF phase III study to characterize the pharmacological properties of Ularitide, evaluate its benefit-risk profile and the appropriate clinical application in patients.

[Read More]